Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

References

• LenrootRBustilloJRLaurielloJKeithSJIntegrated treatment of schizophreniaPsychiatr Services2003541114991507
   Web of Science ®Google Scholar
• TurnerMSStewartDWReview of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychosesJ Psychopharmacol2006206 Suppl203717046985
   PubMed Web of Science ®Google Scholar
• KaneJMLeuchtSCarpenterDDochertyJPExpert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders, 2013The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364Suppl 1251914640142
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association; Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJWFSBP Task Force on Treatment Guidelines for SchizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry2005613219116173147
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJWFSBP Task Force on Treatment Guidelines for SchizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• KreyenbuhlJBuchananRWDickersonFBDixonLBSchizophrenia Patient Outcomes Research Team (PORT)The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009Schizophr Bull20103619410319955388
   PubMed Web of Science ®Google Scholar
• NaberDMoritzSLambertMImprovement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugsSchizophr Res2001501–2798811378316
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDSOHO advisory boardEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• CiudadAOlivaresJMBousoñoMGómezJCAlvarezEImprovement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trialProg Neuropsychopharmacol Biol Psychiatry20063081515152216820255
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAscher-SvanumHOsuntokunOJenKYGomezJCChange in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsBMC Psychiatry2011118721586165
   PubMed Web of Science ®Google Scholar
• WitteMMCaseMGSchuhKJAscher-SvanumHEffects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophreniaCurr Med Res Opin201228331532322236137
   PubMed Web of Science ®Google Scholar
• MasandPSRocaMTurnerMSKaneJMPartial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a reviewPrim Care Companion J Clin Psychiatry200911414715419750066
   PubMedGoogle Scholar
• FleischhackerWWOehlMAHummerMFactors influencing compliance in schizophrenia patientsJ Clin Psychiatry200364Suppl 16101314680413
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
   PubMed Web of Science ®Google Scholar
• LaurielloJLambertTAndersenSLinDTaylorCCMcDonnellDAn 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJ Clin Psychiatry200869579079918452346
   PubMed Web of Science ®Google Scholar
• KaneJMDetkeHCNaberDOlanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophreniaAm J Psychiatry2010167218118920008947
   PubMed Web of Science ®Google Scholar
• DetkeHCWeidenPJLlorcaPMComparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophreniaJ Clin Psychopharmacol4282014 [Epub ahead of print]
   Web of Science ®Google Scholar
• HeinrichsDWHanlonTECarpenterWTJrThe Quality of Life Scale: an instrument for rating the schizophrenic deficit syndromeSchizophr Bull19841033883986474101
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNovickDHaroJMAguadoJCuiZEmpirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophreniaQuality of Life Research20132282085209423239123
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology–RevisedRockville, MDUS Department of Health, Education, and Welfare1976
   Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRRWhat does the PANSS mean?Schizophr Res2005792–323123815982856
   PubMed Web of Science ®Google Scholar
• DanAKumarSAvasthiAGroverSA comparative study on quality of life of patients of schizophrenia with and without depressionPsychiatry Res2011189218518921453977
   PubMed Web of Science ®Google Scholar
• RitsnerMSArbitmanMLiskerAPonizovskyAMTen-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factorsQual Life Res20112161075108421964946
   PubMed Web of Science ®Google Scholar
• MohamedSRosenheckRSwartzMStroupSLiebermanJAKeefeRSRelationship of cognition and psychopathology to functional impairment in schizophreniaAm J Psychiatry2008165897898718450928
   PubMed Web of Science ®Google Scholar
• de JongJTKomproeIHA 15-year open study on a cohort of West-African out-patients with a chronic psychosisSoc Psychiatry Psychiatr Epidemiol2006411189790316964449
   PubMed Web of Science ®Google Scholar
• LambertMDe MarinisTPfeilJNaberDSchreinerAEstablishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatmentEur Psychiatry201025422022919926263
   PubMed Web of Science ®Google Scholar
• BarnettPGScottJYRosenheckRACSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia?Schizophr Res20111301–3343921514794
   PubMed Web of Science ®Google Scholar